Developer docs
API playgroundTry for free, no card

Search company profiles

Antabio

Full company profile

uuid00021n2

Namestring
Antabio
Legal namestring
ANTABIO
Websiteurl
antabio.com
Company typeenum
Private
Founded yearint
2012
Descriptiontext

Antabio is a privately-held, clinical-stage biopharmaceutical company founded in 2012 and headquartered in Labège, France (near Toulouse), developing novel antibacterial treatments that target drug-resistant pathogens identified as critical priorities by the WHO and CDC. The company is led by founding CEO Marc Lemonnier and supported by a leadership team drawn predominantly from Novexel, GSK, Pfizer, AstraZeneca, and Boehringer Ingelheim. With approximately 30 employees, Antabio operates a lean R&D model focused on small-molecule therapeutics rather than biologics, and has raised more than €50 million cumulatively across equity rounds and non-dilutive grants.

The company's core asset is MEM-PIL (meropenem-pilabactam, formerly MEM-ANT3310), a next-generation β-lactam/β-lactamase inhibitor combination in which pilabactam — a proprietary diazabicyclooctane (DBO) inhibitor — uniquely blocks Class A, C, and D serine beta-lactamases to restore meropenem efficacy against carbapenem-resistant Acinetobacter baumannii (CRAB), carbapenem-resistant Enterobacterales (CRE), and Pseudomonas aeruginosa. MEM-PIL completed Phase 1 in September 2024 and is in Phase 2 preparation. The pipeline additionally includes ANT2681 (a metallo-beta-lactamase inhibitor for NDM-producing CRE), PEi (an inhaled Pseudomonas elastase inhibitor for chronic respiratory disease), ANT3273 (a Pseudomonas biofilm inhibitor for cystic fibrosis), and two discovery platforms: AGAR-dp, a three-project collaboration with GARDP, and INTABIO-dp, an internal novel-target program.

Antabio has no commercial revenue and no approved products; its business model relies on non-dilutive grant funding (Wellcome Trust, CARB-X, Bpifrance, French ARPEGE program) for current R&D operations, with planned future revenue from out-licensing or co-development partnerships with large pharmaceutical companies holding hospital sales infrastructure, and ultimately from product sales concentrated in hospital ICUs and infectious disease specialty channels. The company holds FDA QIDP designations on both MEM-PIL and ANT2681, providing five-year data exclusivity extensions and priority review eligibility, plus EMA PRIME designation on MEM-PIL. Key institutional and strategic investors include AMR Action Fund (Series B lead), EIC Fund, BNP Paribas Développement, Turenne/Relyens Santé, and IRDI Capital Investment.

Short descriptiontext

Antabio is a clinical-stage French biopharmaceutical company developing novel antibacterial resistance-breakers, with lead candidate MEM-PIL (meropenem-pilabactam) targeting severe hospital infections caused by WHO/CDC critical priority pathogens including CRAB, CRE, and Pseudomonas aeruginosa.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersLabège, France
HQ citystring
Labège
HQ countrystring
France
HQ regionstring
Europe
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
antibacterial drug development, beta-lactamase inhibitors, antimicrobial resistance therapeutics, hospital infection treatments, carbapenem-resistant infections
Industry2 codes
PRIMARYHLAIAAAG
Infectious Disease & Antimicrobials Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAIACAM
Infectious Disease Specialty Pharmaceuticals (Non-vaccine)
NAICS code1 code
  • Biological Product (except Diagnostic) Manufacturing325414
SIC code1 code
  • Biological Products, (No Disgnostic Substances)2836
Product category
Infectious Disease Therapeutics
Social media profiles2 records
GTM motion3 records

Each record includes

Type, Description, Source

Revenue model3 records
1Pharmaceutical Product Sales
TypeOne Time License
Description

Revenue from sales of novel antibacterial drugs, once approved. The company is developing treatments for severe hospital infections targeting WHO and CDC critical priority pathogens. Given the QIDP and Fast Track designations, the company may pursue accelerated approval pathways.

antabio.com
2Licensing and Partnership Deals
TypeLicensing Royalties
Description

Potential licensing agreements with larger pharmaceutical companies for development and commercialization rights in specific territories or indications.

antabio.com
3Non-Dilutive Funding
TypeProfessional Services
Description

Grants and awards from organizations such as Wellcome Trust, CARB-X, and government programs (French government ARPEGE program) to fund R&D activities.

antabio.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Operations, Marketing or Sales, Others
GTM typeB2B
B2B
Offering typeServices
Services
Brand1 of 5 records shown
1MEM-PIL (formerly MEM-ANT3310)
Description

Meropenem-Pilabactam, a next-generation beta-lactam/beta-lactamase inhibitor combination for treating multi drug-resistant infections in hospital wards and ICUs

antabio.com
+4 more records
Core offering1 text field

Antabio is a clinical-stage biopharmaceutical company developing novel small-molecule antibacterial drugs, principally a next-generation beta-lactam/beta-lactamase inhibitor combination (meropenem-pilabactam, MEM-PIL) for treating life-threatening multi-drug-resistant infections in hospital wards and ICUs. Its pipeline also includes an inhaled Pseudomonas elastase inhibitor for chronic respiratory diseases and early-stage metallo-beta-lactamase inhibitors targeting WHO and CDC critical priority pathogens.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • ANT3310 restores meropenem susceptibility in 95% of A. baumannii clinical isolates tested
+2 more records
Product overview1 text field

Antabio is a clinical-stage biopharmaceutical company developing a diversified pipeline of novel antibacterial treatments targeting WHO and CDC critical-priority drug-resistant pathogens. The core product is MEM-PIL (meropenem-pilabactam), a next-generation β-lactam/β-lactamase inhibitor combination for severe hospital infections. Supporting programs include PEi (Pseudomonas Elastase Inhibitor) for chronic respiratory diseases, ANT2681 (Metallo Beta-Lactamase Inhibitor) for NDM-producing CRE, and ANT3273 for cystic fibrosis. Discovery platforms AGAR-dp (with GARDP) and INTABIO-dp advance additional novel mechanisms through hit-to-lead development.

Product and service4 records
1MEM-PIL (Meropenem-Pilabactam)
CategoryCore product (clinical-stage antibacterial combination)
Description

Next-generation β-lactam/β-lactamase inhibitor (BL/BLI) combination combining meropenem with pilabactam (formerly ANT3310), designed to treat life-threatening multi drug-resistant infections in hospital wards and ICUs. Targets carbapenem-resistant Acinetobacter baumannii (CRAB), carbapenem-resistant Enterobacterales (CRE), and Pseudomonas aeruginosa, as well as susceptible Gram-positives and anaerobes. Currently in clinical development with FDA QIDP designation for cUTI, cIAI, HABP, VABP and EMA PRIME designation.

2PEi (Pseudomonas Elastase Inhibitors)
CategoryPipeline program (inhaled antibacterial adjunct)
Description

Inhaled small-molecule drug targeting the LasB elastase virulence factor of Pseudomonas aeruginosa, designed as an adjunct to existing antibiotic therapy for chronic respiratory diseases including bronchiectasis, cystic fibrosis, asthma, and COPD. Administered via nebulizer to reduce tissue damage and enhance pathogen clearance. Funded by CARB-X and Wellcome Trust.

3ANT2681 (Metallo Beta-Lactamase Inhibitor)
CategoryPipeline program (MBL inhibitor combination)
Description

Novel metallo beta-lactamase inhibitor combined with meropenem for treatment of MBL-producing carbapenem-resistant Enterobacterales, particularly NDM-producing strains. Restores meropenem susceptibility in over 90% of NDM-producing clinical isolates of Enterobacteriaceae. Holds FDA QIDP designation for cUTI.

4ANT3273 (Pseudomonas Biofilm/Lung Infection Inhibitor)
CategoryPipeline program (Pseudomonas biofilm inhibitor)
Description

Novel class, novel mode of action treatment targeting Pseudomonas aeruginosa infections in chronic pulmonary diseases. Funded by Wellcome Trust and CARB-X for cystic fibrosis applications.

Scale indicator10 records

Each record includes

Type, Value, Description, Source

Partnership5 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-03-23
Description

Joint collaboration to accelerate early-stage antibiotic discovery, focusing on hit-to-lead projects targeting carbapenem-resistant Gram-negative bacteria. GARDP brings its discovery programme with 280,000+ compounds screened, while Antabio contributes its expertise in medicinal chemistry, microbiology, and early ADMET profiling. The partnership aims to advance novel treatments for life-threatening infections from WHO priority pathogens.

Strategic tierMajorTypeStrategic or Co-development PartnerAnnounced on2022-01-06
Description

Partnership within the ARPEGE consortium focused on improving diagnostics for antibiotic resistance through AI-powered sequencing-based susceptibility testing solutions. bioMérieux contributes its expertise in in vitro diagnostics to optimize patient care and reduce healthcare costs.

3Hospices Civils de Lyon (HCL)
Strategic tierMajorTypeStrategic or Co-development PartnerAnnounced on2022-01-06
Description

Partnership within the ARPEGE consortium for developing EpiTrack - an automated real-time epidemic surveillance system for early detection of resistant bacteria outbreaks in hospitals.

antabio.com
Strategic tierMajorTypeStrategic or Co-development PartnerAnnounced on2022-01-06
Description

Partnership within the ARPEGE consortium developing new economic models for sustainable enhancement of antibiotic innovation value. Led by Jean Tirole (2014 Nobel Prize in Economics).

Strategic tierCoreTypeTechnology or IntegrationAnnounced on2014-03-10
Description

Drug discovery collaboration funded by Wellcome Trust. Argenta provided medicinal chemistry, computer-aided drug design, and ADME/PK services. Successfully achieved milestone identifying novel lead series of pan-metallo beta-lactamase inhibitors.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Developed plazomicin (Zemdri) for complicated UTIs caused by MDR Enterobacteriaceae; filed for bankruptcy shortly after FDA approval in 2018. Important cautionary comparable demonstrating the antibiotic commercial market risk that Antabio also faces.

TypeDirect peer
Description

Developed delafloxacin (Baxdela) for acute bacterial skin infections and CABP. Filed for bankruptcy in 2019 and was acquired by Cempra. Notable as a cautionary comparable illustrating the commercial challenges of novel antibiotic launches.

TypeDirect peer
Description

Developed and commercialized omadacycline (Nuzyra) for CABP and ABSSSI, a tetracycline-class antibiotic active against MDR pathogens. Acquired by Gurnet Point Capital and Novo Holdings in 2023. Comparable as a developer of novel mechanism antibiotics for serious infections.

TypeEmerging player
Description

Clinical-stage company developing defined bacterial consortia for recurrent C. difficile infection and other serious infections. Adjacent comparable as a developer of novel anti-infective approaches targeting resistant pathogens, though using a fundamentally different biological modality.

TypeDirect peer
Description

Developed eravacycline (Xerava) for complicated intra-abdominal and urinary tract infections caused by MDR pathogens, including carbapenem-resistant Enterobacteriaceae. Acquired by La Jolla Pharmaceutical Company in 2020. Closely comparable in target indications and mechanism class.

TypeDirect peer
Description

Clinical-stage biopharmaceutical company developing novel antibiotics for MDR Gram-negative infections, including tebipenem pivoxil and SPR206 (a polymyxin). Comparable as a similarly-staged developer of novel mechanism antibiotics targeting WHO priority pathogens.

TypeBroad incumbent
Description

Large Japanese pharmaceutical company that developed and commercialized cefiderocol (Fetroja) for MDR Gram-negative infections including CRAB, CRE, and Pseudomonas. Direct competitive incumbent to Antabio's MEM-PIL with established hospital commercialization infrastructure.

TypeDirect peer
Description

Clinical-stage antibacterial developer with leading program cefepime-taniborbactam targeting MDR Gram-negative infections including CRE. Most direct comparable as a similarly-sized, similarly-staged developer of beta-lactam/beta-lactamase inhibitor combinations targeting WHO priority pathogens.

TypeDirect peer
Description

Developed sulbactam-durlobactam (Xacduro) for carbapenem-resistant Acinetobacter baumannii (CRAB) infections, approved by FDA in 2023. Acquired by Innoviva. Directly comparable as developer of beta-lactamase inhibitor combinations targeting the same WHO priority pathogens as Antabio.

TypeDirect peer
Description

Clinical-stage company developing oral and IV antibiotics (sulopenem) for Gram-negative infections including complicated UTIs. Comparable as a similarly-staged developer targeting multi-drug resistant Gram-negative pathogens with hospital-focused positioning.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers1 record

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles21 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance2 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds17 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors15 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Antabio

Infectious Disease Therapeuticsantabio.com

Antabio is a clinical-stage French biopharmaceutical company developing novel antibacterial resistance-breakers, with lead candidate MEM-PIL (meropenem-pilabactam) targeting severe hospital infections caused by WHO/CDC critical priority pathogens including CRAB, CRE, and Pseudomonas aeruginosa.

What Antabio does

Antabio is a privately-held, clinical-stage biopharmaceutical company founded in 2012 and headquartered in Labège, France (near Toulouse), developing novel antibacterial treatments that target drug-resistant pathogens identified as critical priorities by the WHO and CDC. The company is led by founding CEO Marc Lemonnier and supported by a leadership team drawn predominantly from Novexel, GSK, Pfizer, AstraZeneca, and Boehringer Ingelheim. With approximately 30 employees, Antabio operates a lean R&D model focused on small-molecule therapeutics rather than biologics, and has raised more than €50 million cumulatively across equity rounds and non-dilutive grants.

The company's core asset is MEM-PIL (meropenem-pilabactam, formerly MEM-ANT3310), a next-generation β-lactam/β-lactamase inhibitor combination in which pilabactam — a proprietary diazabicyclooctane (DBO) inhibitor — uniquely blocks Class A, C, and D serine beta-lactamases to restore meropenem efficacy against carbapenem-resistant Acinetobacter baumannii (CRAB), carbapenem-resistant Enterobacterales (CRE), and Pseudomonas aeruginosa. MEM-PIL completed Phase 1 in September 2024 and is in Phase 2 preparation. The pipeline additionally includes ANT2681 (a metallo-beta-lactamase inhibitor for NDM-producing CRE), PEi (an inhaled Pseudomonas elastase inhibitor for chronic respiratory disease), ANT3273 (a Pseudomonas biofilm inhibitor for cystic fibrosis), and two discovery platforms: AGAR-dp, a three-project collaboration with GARDP, and INTABIO-dp, an internal novel-target program.

Antabio has no commercial revenue and no approved products; its business model relies on non-dilutive grant funding (Wellcome Trust, CARB-X, Bpifrance, French ARPEGE program) for current R&D operations, with planned future revenue from out-licensing or co-development partnerships with large pharmaceutical companies holding hospital sales infrastructure, and ultimately from product sales concentrated in hospital ICUs and infectious disease specialty channels. The company holds FDA QIDP designations on both MEM-PIL and ANT2681, providing five-year data exclusivity extensions and priority review eligibility, plus EMA PRIME designation on MEM-PIL. Key institutional and strategic investors include AMR Action Fund (Series B lead), EIC Fund, BNP Paribas Développement, Turenne/Relyens Santé, and IRDI Capital Investment.

Antabio firmographics

Firmographics
Name
Antabio
Legal name
ANTABIO
Website
https://antabio.com
Company type
Private
Founded year
2012
Operating status
Operating
Headcount range
11–50 employees
Short description
Antabio is a clinical-stage French biopharmaceutical company developing novel antibacterial resistance-breakers, with lead candidate MEM-PIL (meropenem-pilabactam) targeting severe hospital infections caused by WHO/CDC critical priority pathogens including CRAB, CRE, and Pseudomonas aeruginosa.
Ownership category
akta.pro rank

Antabio industry classification

Industry
Product category
Infectious Disease Therapeutics
NAICS
Biological Product (except Diagnostic) Manufacturing (325414)
SIC
Biological Products, (No Disgnostic Substances) (2836)
akta.pro industry
PRIMARYHLAIAAAG
Infectious Disease & Antimicrobials Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAIACAM
Infectious Disease Specialty Pharmaceuticals (Non-vaccine)

Keywords

  • Antibacterial drug development
  • Beta-lactamase inhibitors
  • Antimicrobial resistance therapeutics
  • Hospital infection treatments
  • Carbapenem-resistant infections

Where Antabio is headquartered

Location

Headquarters

HQ city
Labège
HQ country
France
HQ region
Europe

Offices1 record

Markets served

Antabio business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales, Others

Revenue model

  1. Pharmaceutical Product Sales: Revenue from sales of novel antibacterial drugs, once approved. The company is developing treatments for severe hospital infections targeting WHO and CDC critical priority pathogens. Given the QIDP and Fast Track designations, the company may pursue accelerated approval pathways.
  2. Licensing and Partnership Deals: Potential licensing agreements with larger pharmaceutical companies for development and commercialization rights in specific territories or indications.
  3. Non-Dilutive Funding: Grants and awards from organizations such as Wellcome Trust, CARB-X, and government programs (French government ARPEGE program) to fund R&D activities.

Go-to-market motion3 records

Distribution channels1 record

Marketing channels5 records

Antabio product offering

Product offering

Core offering

Antabio is a clinical-stage biopharmaceutical company developing novel small-molecule antibacterial drugs, principally a next-generation beta-lactam/beta-lactamase inhibitor combination (meropenem-pilabactam, MEM-PIL) for treating life-threatening multi-drug-resistant infections in hospital wards and ICUs. Its pipeline also includes an inhaled Pseudomonas elastase inhibitor for chronic respiratory diseases and early-stage metallo-beta-lactamase inhibitors targeting WHO and CDC critical priority pathogens.

Product overview

Antabio is a clinical-stage biopharmaceutical company developing a diversified pipeline of novel antibacterial treatments targeting WHO and CDC critical-priority drug-resistant pathogens. The core product is MEM-PIL (meropenem-pilabactam), a next-generation β-lactam/β-lactamase inhibitor combination for severe hospital infections. Supporting programs include PEi (Pseudomonas Elastase Inhibitor) for chronic respiratory diseases, ANT2681 (Metallo Beta-Lactamase Inhibitor) for NDM-producing CRE, and ANT3273 for cystic fibrosis. Discovery platforms AGAR-dp (with GARDP) and INTABIO-dp advance additional novel mechanisms through hit-to-lead development.

Differentiator

Problem solved

Functional benefit

Brands

  • MEM-PIL (formerly MEM-ANT3310): Meropenem-Pilabactam, a next-generation beta-lactam/beta-lactamase inhibitor combination for treating multi drug-resistant infections in hospital wards and ICUs
  • PEi
  • ANT2681
  • AGAR-dp
  • INTABIO-dp

Products and services

  • MEM-PIL (Meropenem-Pilabactam) Next-generation β-lactam/β-lactamase inhibitor (BL/BLI) combination combining meropenem with pilabactam (formerly ANT3310), designed to treat life-threatening multi drug-resistant infections in hospital wards and ICUs. Targets carbapenem-resistant Acinetobacter baumannii (CRAB), carbapenem-resistant Enterobacterales (CRE), and Pseudomonas aeruginosa, as well as susceptible Gram-positives and anaerobes. Currently in clinical development with FDA QIDP designation for cUTI, cIAI, HABP, VABP and EMA PRIME designation.
  • PEi (Pseudomonas Elastase Inhibitors) Inhaled small-molecule drug targeting the LasB elastase virulence factor of Pseudomonas aeruginosa, designed as an adjunct to existing antibiotic therapy for chronic respiratory diseases including bronchiectasis, cystic fibrosis, asthma, and COPD. Administered via nebulizer to reduce tissue damage and enhance pathogen clearance. Funded by CARB-X and Wellcome Trust.
  • ANT2681 (Metallo Beta-Lactamase Inhibitor) Novel metallo beta-lactamase inhibitor combined with meropenem for treatment of MBL-producing carbapenem-resistant Enterobacterales, particularly NDM-producing strains. Restores meropenem susceptibility in over 90% of NDM-producing clinical isolates of Enterobacteriaceae. Holds FDA QIDP designation for cUTI.
  • ANT3273 (Pseudomonas Biofilm/Lung Infection Inhibitor) Novel class, novel mode of action treatment targeting Pseudomonas aeruginosa infections in chronic pulmonary diseases. Funded by Wellcome Trust and CARB-X for cystic fibrosis applications.

Quantifiable outcome

  • ANT3310 restores meropenem susceptibility in 95% of A. baumannii clinical isolates tested
  • +2 more outcomes

Companies that use Antabio

Customer profile

Named customers1 record

Segments1 record

Ideal customer profiles3 records

Antabio technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature3 records

Antabio partnerships and signals

Strategic signal

Partnerships

Five partnerships are on record, tiered core and major.

  • GARDP (Global Antibiotic Research & Development Partnership)coreStrategic or Co-development Partner · 23 March 2026Joint collaboration to accelerate early-stage antibiotic discovery, focusing on hit-to-lead projects targeting carbapenem-resistant Gram-negative bacteria. GARDP brings its discovery programme with 280,000+ compounds screened, while Antabio contributes its expertise in medicinal chemistry, microbiology, and early ADMET profiling. The partnership aims to advance novel treatments for life-threatening infections from WHO priority pathogens.
  • bioMérieuxmajorStrategic or Co-development Partner · 6 January 2022Partnership within the ARPEGE consortium focused on improving diagnostics for antibiotic resistance through AI-powered sequencing-based susceptibility testing solutions. bioMérieux contributes its expertise in in vitro diagnostics to optimize patient care and reduce healthcare costs.
  • Hospices Civils de Lyon (HCL)majorStrategic or Co-development Partner · 6 January 2022Partnership within the ARPEGE consortium for developing EpiTrack - an automated real-time epidemic surveillance system for early detection of resistant bacteria outbreaks in hospitals.
  • Toulouse School of Economics (TSE)majorStrategic or Co-development Partner · 6 January 2022Partnership within the ARPEGE consortium developing new economic models for sustainable enhancement of antibiotic innovation value. Led by Jean Tirole (2014 Nobel Prize in Economics).
  • Argenta (Galapagos NV)coreTechnology or Integration · 10 March 2014Drug discovery collaboration funded by Wellcome Trust. Argenta provided medicinal chemistry, computer-aided drug design, and ADME/PK services. Successfully achieved milestone identifying novel lead series of pan-metallo beta-lactamase inhibitors.

Scale indicators10 records

Recent moves6 records

Expansion highlights5 records

Antabio competitors and assessment

Company assessment

Direct peers

  • Achaogen: Developed plazomicin (Zemdri) for complicated UTIs caused by MDR Enterobacteriaceae; filed for bankruptcy shortly after FDA approval in 2018. Important cautionary comparable demonstrating the antibiotic commercial market risk that Antabio also faces.
  • Melinta Therapeutics: Developed delafloxacin (Baxdela) for acute bacterial skin infections and CABP. Filed for bankruptcy in 2019 and was acquired by Cempra. Notable as a cautionary comparable illustrating the commercial challenges of novel antibiotic launches.
  • Paratek Pharmaceuticals: Developed and commercialized omadacycline (Nuzyra) for CABP and ABSSSI, a tetracycline-class antibiotic active against MDR pathogens. Acquired by Gurnet Point Capital and Novo Holdings in 2023. Comparable as a developer of novel mechanism antibiotics for serious infections.
  • Tetraphase Biosciences: Developed eravacycline (Xerava) for complicated intra-abdominal and urinary tract infections caused by MDR pathogens, including carbapenem-resistant Enterobacteriaceae. Acquired by La Jolla Pharmaceutical Company in 2020. Closely comparable in target indications and mechanism class.
  • Spero Therapeutics: Clinical-stage biopharmaceutical company developing novel antibiotics for MDR Gram-negative infections, including tebipenem pivoxil and SPR206 (a polymyxin). Comparable as a similarly-staged developer of novel mechanism antibiotics targeting WHO priority pathogens.
  • VenatoRx Pharmaceuticals: Clinical-stage antibacterial developer with leading program cefepime-taniborbactam targeting MDR Gram-negative infections including CRE. Most direct comparable as a similarly-sized, similarly-staged developer of beta-lactam/beta-lactamase inhibitor combinations targeting WHO priority pathogens.
  • Entasis Therapeutics: Developed sulbactam-durlobactam (Xacduro) for carbapenem-resistant Acinetobacter baumannii (CRAB) infections, approved by FDA in 2023. Acquired by Innoviva. Directly comparable as developer of beta-lactamase inhibitor combinations targeting the same WHO priority pathogens as Antabio.
  • Iterum Therapeutics: Clinical-stage company developing oral and IV antibiotics (sulopenem) for Gram-negative infections including complicated UTIs. Comparable as a similarly-staged developer targeting multi-drug resistant Gram-negative pathogens with hospital-focused positioning.

Emerging players

  • Vedanta Biosciences: Clinical-stage company developing defined bacterial consortia for recurrent C. difficile infection and other serious infections. Adjacent comparable as a developer of novel anti-infective approaches targeting resistant pathogens, though using a fundamentally different biological modality.

Broad incumbents

  • Shionogi: Large Japanese pharmaceutical company that developed and commercialized cefiderocol (Fetroja) for MDR Gram-negative infections including CRAB, CRE, and Pseudomonas. Direct competitive incumbent to Antabio's MEM-PIL with established hospital commercialization infrastructure.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

Antabio social profiles

Digital presence

Antabio compliance and trust

Trust signal

Compliance2 records

Antabio financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Antabio leadership team

Management profile

Number of profiles

Profiles21 records

Antabio funding detail

Funding detail

Funding overview

Funding rounds17 records

Investors15 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Antabio M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Antabio

What does Antabio do?

Antabio is a clinical-stage biopharmaceutical company developing novel small-molecule antibacterial drugs, principally a next-generation beta-lactam/beta-lactamase inhibitor combination (meropenem-pilabactam, MEM-PIL) for treating life-threatening multi-drug-resistant infections in hospital wards and ICUs. Its pipeline also includes an inhaled Pseudomonas elastase inhibitor for chronic respiratory diseases and early-stage metallo-beta-lactamase inhibitors targeting WHO and CDC critical priority pathogens.

Is Antabio a public or private company?

Antabio is a private company. It is classified as venture growth investor backed and is currently operating.

When was Antabio founded?

Antabio was founded in 2012. It employs 11 to 50 people.

Where is Antabio based?

Antabio is headquartered in Labège, France, in the Europe region.

How does Antabio make money?

Three revenue lines are on record. Pharmaceutical Product Sales are the primary driver. The others are licensing and Partnership Deals and non-Dilutive Funding.

Who are Antabio's main competitors?

Direct peers on record are Achaogen, Melinta Therapeutics, Paratek Pharmaceuticals, Tetraphase Biosciences, Spero Therapeutics, VenatoRx Pharmaceuticals, Entasis Therapeutics and Iterum Therapeutics. Vedanta Biosciences is listed as an emerging player. Shionogi is listed as a broad incumbent.

Does Antabio have an API?

No public API is recorded for Antabio.

What industry is Antabio in?

Antabio's product category is Infectious Disease Therapeutics. Its primary akta.pro industry code is HLAIAAAG, Infectious Disease & Antimicrobials Pharmaceuticals, with a secondary code of HLAIACAM, Infectious Disease Specialty Pharmaceuticals (Non-vaccine). Its NAICS code is 325414 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
FinSMEsAntabio Raises €25M in Series B FundingAntabio, a clinical stage biopharmaceutical company based in Labège, France, raised €25M in Series B funding to support the clinical development of its antibacterial product MEM-ANT3310, which is currently in phase 1 trials. The funding round included participation from multiple investors such as AMR Action Fund, BNP Paribas Développement, and others. Antabio focuses on developing treatments for drug-resistant infections, particularly targeting life-threatening respiratory infections.PharmiWeb.comANTABIO Raises €25 Million in Series B FinancingAntabio SAS announced the completion of a €25 million Series B financing round, with investments from the AMR Action Fund, the EIC Fund, and existing shareholders. The funds will support the clinical development and Phase 2 studies of MEM-ANT3310, an antibacterial combination targeting drug-resistant Gram-negative pathogens.GlobeNewswireAntabio Announces First Subjects Dosed in Phase 1 Clinical Trial of MEM-ANT3310, a Highly Differentiated Antibiotic for Severe Hospital InfectionsAntabio announced the first subjects were dosed in its Phase 1 trial of MEM-ANT3310, a meropenem-ANT3310 combination targeting carbapenem-resistant Gram-negative pathogens. The trial assesses safety, tolerability, and pharmacokinetics of single and multiple ascending doses. The company received €5.5 million in funding in 2022.PrwebKemp Proteins Enter Strategic Partnership for Commercialization of ArtiaBio Technology Platform for Stable Cell Line DevelopmentKemp Proteins signed strategic and material transfer agreements with ArtiaBio to access its proprietary parental cell and vector technology for stable cell line development. The technology is royalty-free and carries no license fee on success. Kemp Proteins aims to expand its bioservices portfolio under ISO quality systems.PR NewswireAntabio Receives QIDP Designation From the U.S. FDA for the Development of MEM-ANT3310, a Novel Broad-Spectrum Combination Therapy Targeting WHO's Priority PathogensThe U.S. FDA granted Qualified Infectious Disease Product (QIDP) designation to Antabio's MEM-ANT3310, a novel broad-spectrum combination therapy pairing meropenem with the serine beta-lactamase inhibitor ANT3310, for treating four serious hospital-acquired infections including complicated urinary tract infections and bacterial pneumonia. The QIDP status provides a five-year extension of data exclusivity and eligibility for Fast Track Designation and Priority Review, representing a significant regulatory milestone for the drug candidate currently in preclinical development. This is Antabio's second QIDP designation, following one awarded to its metallo beta-lactamase inhibitor ANT2681 in June 2019, and the therapy targets WHO Priority Pathogens including carbapenem-resistant Enterobacteriaceae and Acinetobacter baumannii.PR.comExclusive Interview with Martin Everett, CSO, Antabio, Ahead of the Superbugs & Superdrugs Conference - PR.comMartin Everett, CSO of Antabio, discussed the maturation of the AMR market and his presentation at the Superbugs & Superdrugs conference in London. He highlighted the spread of NDM-mediated carbapenem resistance and Antabio's novel beta-lactam/beta-lactamase combination as a targeted solution.PR NewswireAntabio Awarded $4.4 Million From CARB-X for the Further Development of its New Treatment for Pseudomonas aeruginosa Infections in Cystic Fibrosis PatientsAntabio SAS, a French biopharmaceutical company focused on developing antibacterial treatments against WHO critical priority pathogens, has been awarded up to $4.4 million in second tranche funding from CARB-X to advance its Pseudomonas Elastase Inhibitor (PEi) program for treating Pseudomonas aeruginosa infections in cystic fibrosis patients. The funding will support completion of non-GLP preclinical studies and follows successful milestone achievement during the first contractual period, recognizing Antabio's identification of a preclinical candidate. The PEi program aims to develop an inhaled product targeting the LasB elastase virulence factor as an adjunct to existing therapy, with potential to enhance treatment effectiveness for the >80% of adult CF patients suffering from chronic P. aeruginosa infections.FinSMEsBiopharma Company Antabio Raises Additional €5.2M; Closes €12.5M Series AAntabio extended its Series A financing with an additional €5.2M, bringing the total to €12.5M. The funds will accelerate development of its MBL inhibitor for drug-resistant infections, complementing a CARB-X grant. The lead product is expected to enter the clinic in 2019.NatureBiotech crowdfunding paves way for angelsFrench crowdfunding platform WiSEED enabled biotech firm ANTABIO to raise seed funding from individual investors, with a second angel investment providing an exit. The UK's BioIndustry Association proposes Citizens' Innovation Funds, allowing individuals to invest up to £15,000 annually. The US SEC still needs to set rules for equity-based crowdfunding.